Powered by OpenAIRE graph
Found an issue? Give us feedback
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/ ZENODOarrow_drop_down
image/svg+xml art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos Open Access logo, converted into svg, designed by PLoS. This version with transparent background. http://commons.wikimedia.org/wiki/File:Open_Access_logo_PLoS_white.svg art designer at PLoS, modified by Wikipedia users Nina, Beao, JakobVoss, and AnonMoos http://www.plos.org/
ZENODO
Preprint
Data sources: ZENODO
Zenodo
Claim

Acamprosate for C9orf72 Frontotemporal Dementia

descriptionPublicationkeyboard_double_arrow_right Preprint Under curationPublisher:Zenodo
Authors: MedicOath Autonomous Discovery Engine;

doi: 10.5281/zenodo.19833367

Acamprosate for C9orf72 Frontotemporal Dementia

Abstract

C9orf72 hexanucleotide repeat expansions cause frontotemporal dementia and ALS through glutamate excitotoxicity and RNA toxicity. Acamprosate modulates glutamate signaling through NMDA receptor antagonism and GABA enhancement, potentially reducing excitotoxic neuronal death in C9orf72-related disease.

Powered by OpenAIRE graph
Found an issue? Give us feedback